The latest price of temsitumumab in 2025 announced by the whole network

Temsitumumab is a fully human monoclonal antibody developed by the British company AstraZeneca. It mainly targets the CTLA-4 target and blocks the interaction between this protein and T cells. Its latest price information and global accessibility in 2025 have attracted much attention. The price of the original drug remains at a high level of US$32,277 per box, and patients still need to pay for it at their own expense.

The latest price of temsitumumab published on the entire network in 2025

In 2025, the price system of remains stable, and the pricing of the original drug is still at a relatively high level, which puts greater economic pressure on patients.

Pricing situation of the original drug

The price of a single box of the original drug is approximately US$32,277, which is relatively expensive and requires patients to purchase it at their own expense. This pricing is basically the same as in previous years, reflecting the high cost of biologics R&D and production.

Current status of the generic drug market

As of now, there are no approved generic drugs of temsilimumab on the market globally. The research and development cycle of biosimilar drugs is long, and it is expected that there will be no price breakthrough in the short term.

Factors affecting price

Drug pricing considers multiple factors such as R&D investment, production technology, and market demand. During the patent protection period, the price of the original drug usually remains high and it is difficult to see a significant decrease.

Understanding drug price dynamics can help patients plan their treatment and look forward to more accessible options in the future.

Global marketing status of temsitumumab

The drug has been approved in multiple major pharmaceutical markets, but has not yet entered the Chinese market, and there are significant differences in accessibility at home and abroad.

Approval time in major countries

The US FDA will take the lead in approval in October 2022, and the EU EMA will follow up in February 2023. Patients in these areas can obtain the drug through formal channels.

China Approval Progress

Currently, the National Medical Products Administration has not yet accepted the marketing application for temsitumumab. According to the conventional approval process, domestic listing will take at least 2-3 years.

Special access channels

Some patients can obtain medication opportunities through licensed medical treatment or participation in clinical trials. These channels are strictly restricted and subject to certain conditions.

Following drug approval progress and maintaining communication with attending doctors are effective ways to obtain the latest marketing information.

Preparation for the administration of temsitumumab

Adequate preparation before administration plays a key role in ensuring the treatment effect and patient safety, and requires the attention of both doctors and patients.

Basic examination items

Basic examinations such as blood routine, liver and kidney function, and electrocardiogram must be completed before treatment. These indicators help evaluate the patient's physical condition and predict treatment tolerance.

Immune status assessment

Focus on examining immune function-related indicators, including lymphocyte subpopulations, etc. The immune status directly affects the treatment effect and the risk of adverse reactions.

Psychological support

Patients and family members need to understand the expected effects and possible side effects of treatment. Professional psychological counseling can help establish reasonable treatment expectations and improve compliance.

Perfect medication preparation lays the foundation for subsequent treatment, and patients should actively cooperate to complete various preparations.